Gabapentin Tablet
Product Images NDC 50090-7714

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-7714). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 01)
Chemical structure of Gabapentin, showing a cyclohexane ring bonded to an amino group (NH2) and a carboxyl group (COOH). This diagram represents the molecular structure of the active ingredient Gabapentin.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 02)
A line chart showing mean pain scores over 8 weeks, comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, and the y-axis shows mean pain scores. The chart includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating lower pain scores for Gabapentin relative to placebo over time.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 03)
Line graph showing mean pain scores over a 7-week period comparing placebo with Gabapentin at doses of 1800 mg/day and 2400 mg/day. The x-axis represents weeks including baseline, and the y-axis measures mean pain score from 0 to 10. The graph is divided into a 3-week dose titration period followed by a 4-week fixed dose period.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 04)
A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses in two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively, with statistical significance indicated.*
FDA Label Image

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)

Image (E4b713f1 A833 4fc7 8a0f 696077ddc280 05)
A scatter plot comparing the percentage difference versus daily dose (mg) of gabapentin across three different studies labeled a, b, and c. The x-axis represents daily dose in milligrams ranging from 600 to 1800, and the y-axis shows percentage difference from 2% to 22%. Each study is indicated by distinct colored markers: black for study a, gray for study b, and white for study c, with data points clustered around 600, 900, 1200, and 1800 mg doses.*
FDA Label Image

Label Image (Lbl500907714)

Label Image (Lbl500907714)
Gabapentin 600 mg oral tablets label from A-S Medication Solutions. The label states each tablet contains 600 mg of gabapentin, with storage instructions to keep at 77 degrees Fahrenheit. The package contains 90 tablets and includes a QR code for dosage instructions. The product NDC is 50090-7714.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.